JP2014507446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507446A5
JP2014507446A5 JP2013555647A JP2013555647A JP2014507446A5 JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5 JP 2013555647 A JP2013555647 A JP 2013555647A JP 2013555647 A JP2013555647 A JP 2013555647A JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
following
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555647A
Other languages
English (en)
Japanese (ja)
Other versions
JP5635708B2 (ja
JP2014507446A (ja
Filing date
Publication date
Priority claimed from US13/478,361 external-priority patent/US8426450B1/en
Application filed filed Critical
Publication of JP2014507446A publication Critical patent/JP2014507446A/ja
Publication of JP2014507446A5 publication Critical patent/JP2014507446A5/ja
Application granted granted Critical
Publication of JP5635708B2 publication Critical patent/JP5635708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555647A 2011-11-29 2012-11-28 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン Active JP5635708B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564537P 2011-11-29 2011-11-29
US61/564,537 2011-11-29
US13/478,361 2012-05-23
US13/478,361 US8426450B1 (en) 2011-11-29 2012-05-23 Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en) 2011-11-29 2012-11-28 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014210716A Division JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Publications (3)

Publication Number Publication Date
JP2014507446A JP2014507446A (ja) 2014-03-27
JP2014507446A5 true JP2014507446A5 (cg-RX-API-DMAC7.html) 2014-06-19
JP5635708B2 JP5635708B2 (ja) 2014-12-03

Family

ID=48094815

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013555647A Active JP5635708B2 (ja) 2011-11-29 2012-11-28 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Country Status (50)

Country Link
US (7) US8426450B1 (cg-RX-API-DMAC7.html)
EP (1) EP2785706B1 (cg-RX-API-DMAC7.html)
JP (3) JP5635708B2 (cg-RX-API-DMAC7.html)
KR (1) KR101979050B1 (cg-RX-API-DMAC7.html)
CN (6) CN106986822B (cg-RX-API-DMAC7.html)
AP (1) AP2014007729A0 (cg-RX-API-DMAC7.html)
AR (1) AR089019A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012346133B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012878B1 (cg-RX-API-DMAC7.html)
CA (1) CA2850644C (cg-RX-API-DMAC7.html)
CL (1) CL2014001280A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990728A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140312A (cg-RX-API-DMAC7.html)
CY (2) CY1118416T1 (cg-RX-API-DMAC7.html)
DK (1) DK2785706T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000115A (cg-RX-API-DMAC7.html)
EA (1) EA026553B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14003642A (cg-RX-API-DMAC7.html)
ES (1) ES2603958T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20200022I1 (cg-RX-API-DMAC7.html)
FR (1) FR20C1029I2 (cg-RX-API-DMAC7.html)
GE (1) GEP201706695B (cg-RX-API-DMAC7.html)
GT (1) GT201400102A (cg-RX-API-DMAC7.html)
HR (1) HRP20161708T1 (cg-RX-API-DMAC7.html)
HU (2) HUE032288T2 (cg-RX-API-DMAC7.html)
IL (1) IL232859B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04907A (cg-RX-API-DMAC7.html)
JO (1) JO3202B1 (cg-RX-API-DMAC7.html)
LT (2) LT2785706T (cg-RX-API-DMAC7.html)
MA (1) MA35836B1 (cg-RX-API-DMAC7.html)
MD (1) MD4539C1 (cg-RX-API-DMAC7.html)
ME (1) ME02561B (cg-RX-API-DMAC7.html)
MX (1) MX2014006423A (cg-RX-API-DMAC7.html)
MY (1) MY165514A (cg-RX-API-DMAC7.html)
NI (1) NI201400043A (cg-RX-API-DMAC7.html)
NL (1) NL301047I2 (cg-RX-API-DMAC7.html)
PE (1) PE20141421A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501199A1 (cg-RX-API-DMAC7.html)
PL (1) PL2785706T3 (cg-RX-API-DMAC7.html)
PT (1) PT2785706T (cg-RX-API-DMAC7.html)
RS (1) RS55448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402044XA (cg-RX-API-DMAC7.html)
SI (1) SI2785706T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201600467T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000165A1 (cg-RX-API-DMAC7.html)
TW (1) TWI638806B (cg-RX-API-DMAC7.html)
UA (1) UA115136C2 (cg-RX-API-DMAC7.html)
UY (1) UY34472A (cg-RX-API-DMAC7.html)
WO (1) WO2013082102A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404787B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
CA2829248C (en) 2010-12-07 2018-04-17 Allison Transmission, Inc. Energy storage system for hybrid electric vehicle
JP5699251B2 (ja) 2011-06-22 2015-04-08 パーデュー、ファーマ、リミテッド、パートナーシップ ジヒドロキシ置換基を包含するtrpv1アンタゴニストおよびその使用
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) * 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
CN109310627B (zh) 2016-06-06 2021-12-14 赫尔森保健股份公司 福奈妥匹坦的生理平衡注射制剂
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
CN108619525B (zh) * 2017-03-15 2020-12-29 和龙 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
CN107698500A (zh) * 2017-10-17 2018-02-16 扬子江药业集团四川海蓉药业有限公司 一种奈妥匹坦的制备方法
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
US11433021B2 (en) * 2018-01-12 2022-09-06 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CN112778370B (zh) * 2019-11-06 2025-09-26 扬子江药业集团江苏海慈生物药业有限公司 一种制备福奈妥匹坦的方法
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) * 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
WO2025036703A1 (en) 2023-08-13 2025-02-20 Helsinn Healthcare Sa Fosnetupitant for administration via intravenous bolus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261730T1 (de) 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
ATE277905T1 (de) * 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
EP1303490B1 (en) 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
MXPA03005169A (es) 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
ES2559475T3 (es) * 2009-11-18 2016-02-12 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos de origen central
US9670200B2 (en) * 2010-01-07 2017-06-06 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
HUE028411T2 (en) * 2010-12-02 2016-12-28 Univ Kansas Precursors and derivatives of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2 (1H) -one \ t
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain

Similar Documents

Publication Publication Date Title
JP2014507446A5 (cg-RX-API-DMAC7.html)
JP2013014622A5 (cg-RX-API-DMAC7.html)
JP2012107057A5 (cg-RX-API-DMAC7.html)
JP2017509667A5 (cg-RX-API-DMAC7.html)
JP2009545527A5 (cg-RX-API-DMAC7.html)
JP2016518337A5 (cg-RX-API-DMAC7.html)
JP2015078230A5 (cg-RX-API-DMAC7.html)
JP2014221779A5 (cg-RX-API-DMAC7.html)
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2012255026A5 (cg-RX-API-DMAC7.html)
JP2013525444A5 (cg-RX-API-DMAC7.html)
JP2018521020A5 (cg-RX-API-DMAC7.html)
JP2012126725A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2015501783A5 (cg-RX-API-DMAC7.html)
JP2014515013A5 (cg-RX-API-DMAC7.html)
JP2017008120A5 (cg-RX-API-DMAC7.html)
JP2011105738A5 (cg-RX-API-DMAC7.html)
JP2015528502A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2013532687A5 (cg-RX-API-DMAC7.html)
JP2017537066A5 (cg-RX-API-DMAC7.html)
JP2013522326A5 (cg-RX-API-DMAC7.html)
EP2833721A4 (en) NICKEL OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.